Eli Lilly says it plans to submit orforglipron to the U.S. Food and Drug Administration for approval as a Type 2 diabetes treatment in 2026. For weight management, it plans to submit the drug to ...

A daily pill from drugmaker Eli Lilly has shown similar effectiveness ... The once-daily pill, called orforglipron, helped patients with Type 2 diabetes during late-stage trials and has shown ...

Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral version of the booming class of drugs ...

Eli Lilly's stock boomed ... of the trial were released. Lilly said its new pill would continue the company's "mission to reduce chronic diseases like type 2 diabetes," which it says is expected ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Eli Lilly's shares were rallying ahead of the opening bell after the drug company's first GLP-1 pill for diabetes and weight loss took a step closer to hitting the market. In premarket trading ...

Eli Lilly experienced a 16% price increase last ... trial for Orforglipron highlight potential new treatments for type 2 diabetes. These innovative steps likely bolstered investor confidence ...

Eli Lilly said ... in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.

Some of the potential iterations of delivery methods Eli Lilly considered for orforglipron ... But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was ...